31.7101.98% ( -0.640 )
Closed: Oct 22, 16:00:00 (EDT)Current ValuationThe current P/E ratio is 85.23, above the reasonable range, cheaper than 1.92% of the time in the past 1 years, and the industry ranks 59/605, the industry Median -1.91.
85.23xP/E
$31.71Stock price
$0.37Earnings per share
85.23xP/E
Stock price$31.71Earnings per share$0.37
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -10.38x
- Typical range
- -11.32x–58.60x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
022446688
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
ABBVUSAbbvie | 80.38x | 231.97% | $503.96B |
CAIUSCaris Life Sciences | 85.23x | 133.14% | $8.96B |
KNSAUSKiniksa Pharmaceuticals | 78.15x | 68.27% | $6.30B |
PHARUSPharming Group NV | 81.20x | 562.50% | $755.20M |
NNNNUSAnbio Biotechnology | 83.37x | -- | $533.84M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
